Picture loading failed.

Anti-C5AR1 therapeutic antibody (Pre-made Avdoralimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Avdoralimab (IPH 5401, formerly NN 8210) is a complement C5a receptor antagonist (Anti-C5aR-215) recombinant human monoclonal antibody, being developed by Innate Pharma, for the treatment of solid tumours, chronic spontaneous urticaria [chronic urticaria in development table], Bullous-pemphigoid and COVID-19 pneumonia.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-039-1mg 1mg 3090
GMP-Bios-ab-039-10mg 10mg 21890
GMP-Bios-ab-039-100mg 100mg 148000
GMP-Bios-ab-039-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-C5AR1 therapeutic antibody (Pre-made Avdoralimab biosimilar,Whole mAb)
INN Name Avdoralimab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesNovo Nordisk;Innate Pharma
Conditions Approvedna
Conditions ActiveBullous pemphigoid;COVID-19;Urticaria;Liver cancer;Non-small cell lung cancer;Solid tumours
Conditions DiscontinuedRheumatoid arthritis
Development Techna